Books Related Topics 
Fierce Pharma
JUNE 12, 2024
A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book. The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug.
Fierce Pharma
SEPTEMBER 7, 2023
After a clutch of lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book—the registry for patents of approved drugs—the Federal Trade Commission (FTC) is getting in on | After multiple lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book, the FTC is getting in on the action.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 25, 2024
With an agreement to make payments totaling $750 million over the next five years, Teva can wipe its slate clean of litigation from Israeli regulators that concerns over a decade's worth of taxes.< < | The deal with the Israel Tax Authority wraps up pending litigation over taxes payable from 2008 to 2020.
Fierce Pharma
DECEMBER 14, 2023
Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019.
Fierce Pharma
NOVEMBER 8, 2023
With a year and change still left before Fujifilm Diosynth cuts the ribbon on a massive biomanufacturing facility in North Carolina, the CDMO has already lined up its first client.
Fierce Pharma
APRIL 30, 2024
FTC is not done with its crackdown on what it views as improper listing of patents in the FDA Orange Book. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. |
Fierce Pharma
NOVEMBER 7, 2023
. | Only two months after the Federal Trade Commission said it was eying a crackdown on improper patents listed by the FDA, the agency has filed challenges against more than 100 patents in the agency's Orange Book. The companies have 30 days to respond.
Expert insights. Personalized for you.
336 
Let's personalize your content